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Abstract
Objective: To examine the evolution of the concept of the symptom cluster through literature synthesis
and identification of knowledge gaps.
Data source: Published literature
Conclusion: A robust body of research has developed showing that clusters of symptoms can be
identified empirically with modest evidence of convergence across methods. The science would benefit
from a coordinated effort of qualitative studies to ensure that appropriate symptoms are evaluated;
empirical symptom cluster identification studies building upon qualitative work; and subgroup
identification studies based on empirically defined symptom clusters.
Implications for Nursing Practice: Work is needed to demonstrate the value of symptom cluster
identification in guiding symptom assessment and management for cancer patients and survivors.
Key words: symptom cluster, cancer, cancer-related symptoms
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Following the UCSF Symptom Management Group challenge to consider the concept of the
“symptom cluster” 1 and a state of the science lecture and paper on the symptom cluster in cancer 2, more
recent publications have examined conceptual and methodological issues in defining symptom clusters 312

. For this article, a literature search of PubMed from 2008 to 2015 was conducted and reference lists of

relevant publications were also scanned for additional publications. This article examines the evolution
over the past 10 years of the concept of the symptom cluster including its definition, related theoretical
concepts, methods of identification, stability of clusters, and identification of symptom cluster subgroups.
The literature is synthesized and knowledge gaps are assessed as a basis for future research.
Definition of a Symptom Cluster
A symptom cluster has been defined as a stable group of concurrent symptoms that are related to
one another and distinct from other symptom clusters 13. Symptoms in a cluster may be related through a
common etiology or mechanism, shared variance, or a common outcome 3. Stability of clusters could
relate to consistency of results across clustering techniques, consistency within cancer populations, or
stability over time. To date, no firm conclusions have been drawn about the minimum number of
symptoms required to form a cluster; two 1,14 or three symptoms 13 have been proposed. The dictionary
defines a cluster as “a number of things of the same kind held together; a group of things” 15. The actual
number of things required is not specified; however, the use of the word “group” carries the implication
that it is more than two.
However, there are arguments in favor of including symptom pairs in the definition of a symptom
cluster. In two clinical studies in advanced cancer patients, a gastro-intestinal symptom cluster was
determined to be made up of two symptoms, nausea and vomiting 16,17. In a large sample of advanced
cancer patients, anxiety-depression was identified as a cluster across three different methods of analysis
18,19

. Given the presence of clinically and statistically meaningful symptom pairs and the potential for

others, it makes sense to include symptom pairs in the definition of a symptom cluster. Another reason to
consider symptom pairs as clusters is that the number and type of symptoms observed in a cluster is
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reflective of the number and type of symptoms that were measured. Measuring a larger number of related
symptoms is likely to increase the number of symptoms included in a particular cluster. When fewer
symptoms are measured, a symptom pair could be a proxy for a cluster with more symptoms. Including
symptom pairs in the definition of a cluster provides an opportunity for a more complete description of
symptom clusters in a specific context.
On the other side of this issue are questions about when a symptom cluster should be considered
complete. As noted above, one determinant of the number of symptoms comprising a cluster is the
number and relevance of the symptoms that are measured. Other determinants include characteristics of
specific cancers (such as, cough and breathlessness associated with lung cancer) 20,21, treatment modalities
(neuropathy related to neurotoxic chemotherapy), and demographics (a body image cluster in women with
gynecological cancers) 22. Acknowledging these influences, experts have begun to advocate for
agreement about a core set of symptoms to be measured across all patients23,24 as well as consideration of
symptom clusters specific to disease 25,26 and treatment types 27. This issue is described more fully in the
paper on assessment of multiple co-occurring symptoms (28).
Related Theoretical Concepts
Across symptom management theories and models, the addition of the concepts of interaction 29,
time 30, and mechanism 31 have proven to be important constructs guiding our scientific understanding of
the symptom cluster. As the science of symptom management has developed, the theories and models
used to describe symptom clusters have expanded to incorporate explicit components. The Theory of
Symptom Management, proposed three components originally: the symptoms experience (addressing
single or multiple symptoms); symptom management; and outcomes 1. Later, this theory was expanded to
include personal, health-illness, and environmental contexts of symptoms 32. The Theory of Unpleasant
Symptoms explicitly described the potential for interaction and/or synergy among multiple symptoms 29.
Through a linear presentation of antecedents, symptoms, and outcomes, it suggested but did not explicitly
identify a time component. Later theoretical models expanded the time component, recognizing that
symptoms can vary considerably over time and that variability in one symptom can influence other
4
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symptoms 33,34. One model, The Symptom Interaction Framework, explicitly identified underlying
symptom “mechanisms” to describe alterations in process or function that could explain the presence of a
group of symptoms 31; mechanisms could be biological, psychological, social, or behavioral.
Methods of Identification of Symptom Clusters
Qualitative methods allow for the exploration of the breadth and complexity of related symptoms.
Four qualitative studies identified symptom clusters (table 1)20-22,35. Women with gynecological cancers
identified the symptoms of tiredness, sleeplessness, pain, depression, and weakness as the most common
cluster experienced by all participants over one year, irrespective of treatment 22. Three other symptom
clusters were identified in this research, all related to chemotherapy (body image, GI and neuropathy). In
a longitudinal qualitative study of symptoms related to lung cancer, a subset of respiratory symptoms
including cough, breathlessness, and fatigue were highlighted as co-occurring, influencing one another,
and triggering other symptoms such as anxiety, depression, pain, and sleep disturbance 21. The
investigators did not discuss why the triggered symptoms were not part of the cluster. In another lung
cancer sample, the core symptoms of fatigue, pain, cough, and breathlessness were associated and
affected one another synergistically 20. However, the investigators noted that participants often focused
on individual symptoms and not all symptoms were given equal weight. In a study of chemotherapyinduced nausea, the investigators explored the possibility that the term nausea could represent a cluster of
symptoms35. They concluded that the nausea experience included a cluster of symptoms that was unique
to each individual. Although the research identified a group of co-occurring symptoms that were
considered separate but related to nausea (vomiting, taste changes, appetite changes, and fatigue), the
investigators did not identify this as a symptom cluster. More rigorous qualitative research is needed to
ensure that symptom clusters identified through patient narrative support or challenge the current
definition of a symptom cluster.
A priori Identification
In oncology symptom research, symptom clusters have been identified using two different
methods: 1) they have been specified “a priori”, meaning formed or conceived beforehand; or 2) they
5
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have been identified using empirically, based on observation (also called “de novo”) methods 3. A priori
refers to symptoms selected as a cluster based on patient qualitative experience, clinical observation of
symptom co-occurrence, or research hypotheses about the relationships among symptoms. Symptom
clusters identified in qualitative studies could be considered a priori if the individuals being studied
determine the symptom selection; alternatively, they could be considered empirical if the clusters are
derived through qualitative data analysis.
Quantitative research has been used to study a priori symptom clusters. In animal studies, a
group of behaviors (asthenia, lethargy, anorexia, weakness, and sleep disturbance) were observed that
became known as “sickness behavior,” a syndrome thought to be the result of inflammatory processes
induced by disease or trauma36,37. This syndrome closely resembles the cluster of symptoms commonly
reported by humans in the context of cancer and its treatment that may include fatigue, sleep disturbance,
pain, depression, and mental confusion. The similarities between human symptoms and animal behaviors
resulted in many investigations in which variations on this group of symptoms were evaluated as a priori
symptom clusters 30,38-43.
A priori symptom clusters have included variations on the symptoms of fatigue, insomnia, pain,
and depressed mood that are related to sickness behaviors (table 2)30,38-44. Quantitative studies have
demonstrated that these clusters meet two criteria defining a cluster: symptoms are related to one another
and have a common influence on outcomes. Most studies used analytic techniques such as correlation,
path analysis, structural equation modeling, or other multivariate methods to examine the relationships
among a group of symptoms. One study showed that fatigue, sleep disturbance, and depression in breast
cancer patients were correlated at each study point; and path analysis showed that symptom severity at
each time point predicted severity of the same symptom at subsequent time points with the exception that
earlier fatigue predicted later depression in pre-menopausal women38. Another study examined temporal
changes in daily symptoms (fatigue sleep disturbance, and depressed mood) selected a priori in women
with gynecological cancers and found that greater sleep disturbance was associated earlier peak fatigue,
and higher levels of fatigue predicted later depressed mood30. Another study modeled fatigue as a latent
6
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variable directly influenced by pain, depressed mood and insomnia43. Results showed direct effects
among all four symptoms as well as mediating effects: the effect of depressed mood on pain was
mediated by insomnia; and the effect of depressed mood on fatigue was mediated by insomnia and pain.
The effect of a presumed symptom cluster on outcomes has also been examined. For example,
multiple regression analysis showed that the cluster of pain, fatigue, insomnia, and mood disturbance
predicted performance status and quality of life in elderly cancer patients39. In another study, pain, the
cluster of fatigue, sleep disturbance, and distress in lung cancer surgery patients was negatively related to
performance status and quality of life41. Only one study examined how related symptoms influenced
outcomes. In a cross-sectional study of fatigue, insomnia, depression, and pain, a cluster was defined as
two or more symptoms directly related to each other and indirectly related to functional performance
(dependent variable)44. Path analysis revealed seven indirect symptom paths to functional performance
for pain and three paths for insomnia which the investigators characterized as synergy among symptoms.
Empirical Identification
The selection of an a priori symptom cluster does not settle the issue of the completeness of a
cluster or the number of symptoms that are or should be included. It is possible that other symptoms
could be part of the cluster but were left out because of a priori selection of symptoms. To address the
completeness issue, an alternative approach has been to use statistical procedures to select and group
symptoms from a larger population of symptoms. Thus, an empirically determined symptom cluster is a
group of symptoms derived from a larger pool of symptoms using statistical procedures (table 3)7,16,45-58.
In this methodology, research participants rate a group of symptoms that are relevant to their situation. A
variety of statistical methods such as principal components analysis, common factor analysis, or cluster
analysis are used to select clusters from the larger pool of symptoms.
Principal Components Analysis (PCA), a type of exploratory factor analysis, is a descriptive data
reduction method based on total variance 59 that combines a larger number of variables into smaller
clusters that are unique and stable. This method does not presume a theoretical basis or underlying
connection among the symptoms within each cluster. PCA has been the method most commonly used
7
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for symptom clustering 16,19,54,58,60. For example two studies of advanced cancer patients used PCA to
identify symptom clusters using the Edmonton Symptom Assessment Scale (ESAS). The first study
identified two clusters: cluster 1 included fatigue, drowsiness, nausea, appetite, and dyspnea; cluster 2
comprised anxiety and depression 46,47. The second study used the ESAS measure, but supplemented it
with 13 additional items 16, identifying four clusters: confusion, neuropsychological, anorexia-cachexia,
and gastro-intestinal clusters. In both studies, symptom clusters differed by age, gender, performance
status, and/or type of cancer. The difference between the study results could also be related to the
symptoms measured. A third study used PCA to identify three clusters in breast cancer patients based on
a 32-item symptom scale: emotional, unwell, and gastro-intestinal clusters 50. The first cluster included
similar symptoms to the
Common Factor analysis (CFA) is another type of exploratory factor analysis that examines
common variance to determine the latent factors underlying a set of variables and develop and/or test
hypotheses about those underlying factors 59. Two symptom cluster studies using CFA illustrate this
point. In a study of breast and prostate cancer patients being treated with radiotherapy, CFA was used to
identify symptom clusters in 160 individuals who rated 32 symptoms on the Memorial Symptom
Assessment Scale 51. At the midpoint of treatment, three clusters were identified: a mood-cognitive
cluster (difficulty concentrating, feeling nervous, feeling sad, worrying, itching, feeling irritable, skin
changes); a sickness behavior cluster (pain, lack of energy, feeling drowsy, difficulty sleeping, sweats);
and a treatment-related cluster (urinary problems and diarrhea). In a separate study, 282 women receiving
chemotherapy or radiotherapy for breast cancer rated twenty symptoms 52. Two symptom clusters were
identified during treatment: a psycho-neurological cluster (pain, fatigue, insomnia, depressed mood,
cognitive disturbance, and hot flashes); and an upper gastro-intestinal cluster (nausea, vomiting,
decreased appetite). The “sickness behavior cluster” in the breast and prostate study was similar to the
“psycho-neurological cluster in the breast cancer study.
Two things are noteworthy. First, the results provided empirical validation of the “sickness
behavior” cluster that was previously identified a priori. Secondly, implicit in the naming of the clusters
8
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was a hypothesis about the underlying mechanism. The “sickness behavior” cluster and the “psychoneurological” cluster both have a hypothesized underlying mechanism of inflammation. Although the
symptoms included in each cluster are slightly different, some of the core symptoms are the same, lending
modest support to the idea that there is a common mechanism underlying this group of symptoms.
Hierarchical Cluster analysis (HCA) is an empirical method for grouping symptoms or people
and separating them from dissimilar groups based on measures of distance, such as Euclidian distance 61.
In a study of 922 advanced cancer patients in a palliative medicine program, HCA was used to group 25
symptoms 53. Seven clusters were identified: fatigue-anorexia-cachexia, psycho-neurological, upper
gastro-intestinal, nausea-vomiting, aero-digestive, debility, and pain clusters. The authors argued that
these clusters were likely to be therapeutically important because treatment of one symptom could
influence or be influenced by another symptom in the cluster. For example, the pain cluster included both
pain and constipation; in advanced cancer, pain is a common problem that is often treated with opioid
analgesics that can induce constipation.
Stability of Symptom Clusters
Consistency across Clustering Techniques. In a number of studies, investigators have searched
for symptom clusters using more than one analytic technique (table 4)19,60,62-67. Looking across clustering
methods, one can observe both similarities and differences in the number and composition of symptom
clusters. A study of 1296 advanced cancer patients illustrated this point 62. The cluster of anxiety and
depression was identified across all three clustering methods (PCA, HCA, and CFA). Two identical
clusters also emerged when analyzed with PCA and HCA: one cluster included appetite, nausea,
wellbeing, and pain; the other included fatigue, drowsiness, and dyspnea. With CFA, only one additional
factor emerged combining all the remaining symptoms into one factor. The investigators concluded that
PCA and HCA were in closer agreement than CFA. Another example of agreement between PCA and
HCA can be seen in a study of 400 patients with inoperable lung cancer 60. Three symptom clusters (pain,
mood, and respiratory) were consistent across three different methods of analysis: Pearson correlation,
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PCA, and HCA. Looking across studies, appetite change, proposed in qualitative research as an
additional component of a nausea-vomiting cluster 35, was confirmed in two empirical analyses 52,56.
Consistency within Cancer Populations. Looking at similar cancer populations, several review
papers concluded that there is little consistency of symptom clusters across samples. For example, a
review of five breast cancer studies found no cluster consistency across studies 10. A review of
gastrointestinal symptom clusters 11 found that 38 of 40 clusters included different symptoms; and a
review of five lung cancer studies showed only nausea/vomiting and a respiratory cluster were common
across two studies 9. In a review of studies of patients with advanced disease, the authors could not
formulate a general consensus of symptom clusters due to variability in symptoms assessed, assessment
measures used, analytic methods, and patient demographics 12.
Stability over Time
Over the past decade, evidence has accumulated in support of the stability of symptom clusters
over time. Symptoms evaluated with exploratory factor analysis at the middle, end, and 1 month after
radiotherapy for breast or prostate cancer showed four relatively similar symptom clusters across time
points: mood-cognitive; treatment-related; sickness-behavior; and pain 51. For breast cancer patients
undergoing treatment, a psycho-neurological symptom cluster was observed via common factor analysis
prior to treatment; this cluster was repeated during treatment and a gastro-intestinal cluster was also
observed 52. Symptom clusters identified before treatment in women with ovarian cancer were repeated
during chemotherapy; additional clusters were observed during treatment that could represent the shortand long-term effects of treatment 49. These studies and many others provide increasing support for the
clustering of symptoms by virtue of their concurrence and stability over time.
Antecedents and Consequences
A better understanding of the antecedents and consequences of a symptom cluster could inform
our understanding of who is likely to experience specific clusters and how the clusters influence their
quality of life. Cluster composition has been shown to differ by age and gender 47 and by performance
status and cancer diagnosis16 in two different studies. In contrast, another study found no differences in
10
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symptom cluster composition based on demographic or clinical factors 52. With regard to consequences
of symptom clusters, the number of symptom clusters experienced 16 and the presence of a specific
symptom cluster 67 were associated with survival/mortality. In addition, more symptoms 41, more severe
symptoms 66, and the presence of specific clusters 56 have predicted poorer quality of life. More work is
needed to point us toward a more robust picture of the demographic and clinical context of specific
symptom clusters as well as the likelihood that specific clusters influence important outcomes including
quality of life and survival.
Identification of Patient Subgroups with a Similar Symptom Experience
Thus far, we have examined the way in which “symptoms” are related to one another. An
alternative approach is to examine differences in the symptoms experience within “subgroups” of
individuals (table 5)68-77. Regardless of how a symptom cluster has been determined (a priori or
empirically), there is likely to be variability in how individuals experience the cluster. One method of
grouping patients is to create composite symptom scores. Sanford and colleagues 76 selected fatigue,
sleep disturbance, depression, anxiety, and confusion as an a priori cluster in women undergoing
chemotherapy for breast cancer. Participants were assigned to a symptom cluster index group based on
the number of abnormal symptom scores at the initial assessment. With the exception of anxiety, the
coherence and stability of each symptom cluster group was demonstrated by similar patterns of symptom
severity and change over time in all four symptoms. Using a similar methodology to classify groups of
breast cancer patients on the basis of fatigue, sleep disturbance, and depression, Liu et al 74 found a
similar pattern of symptom cluster groups across time.
Statistical grouping methods have also been used to evaluate groups of individuals to determine
the prevalence and pattern of symptoms within cluster groups. Hierarchical Cluster analysis (HCA),
previously described as a method for grouping symptoms, has also been used to identify subgroups of
individuals with similar symptom patterns; Latent Class Analysis (LCA) has also been used for this
purpose. Based on HCA of the most common symptoms (fatigue, pain, dyspnea, and insomnia), lung
cancer patients were classified into groups with mild (60%), moderate (28%) or severe (12%) composite
11
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symptom scores 70. Another study used HCA to evaluate severity patterns of the psycho-neurological
symptom cluster (including fatigue, insomnia, pain, depressed mood, and cognitive disturbance) in breast
cancer patients to identify four groups: all low symptoms (26%), all high symptoms (24%), low pain-high
fatigue (19%), and high pain (30%) groups 73. In a separate study, breast cancer patients were classified
using LCA into subgroups based on symptoms (fatigue, insomnia, pain, and depression); subgroups
included all low symptoms (61%), all high symptoms (7%), and low pain-high fatigue (32%) 69. Despite
some variation in results, these studies indicate that groups of cancer patients can be classified according
to similarities in their experience of symptom clusters.
Stability of Symptom Cluster Subgroups over Time
There is some evidence that symptom cluster subgroups endure over time. Prior to radiotherapy,
men with prostate cancer were classified into four subgroups with similar patterns of fatigue, insomnia,
pain, depressed mood, anxiety, and treatment-related symptoms (bowel, urinary, and sexual): all low
symptoms; moderate treatment-related symptoms; all high symptoms; and moderately high fatigue,
depression, and anxiety with few treatment-related symptoms 68. Similar groupings were derived after
treatment. In breast cancer patients undergoing treatment, before treatment subgroups were replicated
during treatment and two new groups emerged: high depressed mood-cognitive disturbance and high
fatigue-insomnia groups 73.
Antecedents and Consequences of Symptom Cluster Subgroups
Symptom cluster subgroups were shown in one study to differ by treatment received,
performance status, and education 73; however, another study observed no differences based on
demographic or clinical factors 74. Considering biomarkers, several investigators were able to
differentiate subgroups based on the presence of rare cytokine gene alleles 69, the additive effects of five
immune response genes 75, or cytokine levels 77. With regard to outcomes, research has shown that
subgroups with more severe symptom clusters had poorer quality of life 70,71, worse functional status 73,
and increased depression and worse mental quality of life 66. Continued work in this domain will benefit
the identification of subgroups at high risk for potentially damaging effects on patient outcomes.
12
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Synthesis and Conclusions
Advances in Defining the Symptom Cluster
There have been significant advances in symptom cluster science over the past decade. With
regard to the definition of a symptom cluster, examples in the literature of clinically meaningful symptom
pairs such as nausea-vomiting 16,17 or anxiety-depression 18 add strength to the argument for including
symptom pairs within the definition of the symptom cluster. More is to be gained than lost in accepting
the more inclusive definition. In addition, several theoretical concepts have been incorporated into
symptom models to guide the study of symptom clusters including evaluation of influences of symptoms
on one another, examination of cluster stability over time, and determination of underlying mechanisms.
An evidence base is developing to support the relevance of these concepts to the science of symptom
clusters.
Advances in Research and Future Directions
It is interesting to note that cancer patients and survivors have been able to recognize and
articulate groups of inter-related symptoms that impacted their quality of life. Symptom cluster science
could benefit from more focused qualitative explorations of symptom clusters across the cancer trajectory
from diagnosis, through treatment, and into survivorship. Learning from patients and survivors which
symptoms co-occur reliably, are most distressing, and/or result in the most interference with functional
status and quality of life will better inform quantitative science by ensuring that all relevant symptoms are
represented in models. This will also enhance the validity of the quantitative models as representations of
the patient-survivor experience. It may also be useful to use qualitative research to validate statistically
derived symptom clusters as congruent with patient symptoms experience.
There is now a robust body of research showing that clusters of symptoms can be identified
empirically using a variety of statistical methods. There is modest evidence of convergence across
empirical clustering methods applied within the same sample. However, there is less evidence of
convergence and validation of clusters across similar samples using the same or different analytic
strategy. Therefore, replication studies are needed to ensure the reproducibility and usefulness of the
13
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statistically identifiedsymptom cluster in the clinical setting. Looking across methods used in symptom
cluster research to date, the science would benefit from a coordinated effort of qualitative studies to
ensure that appropriate symptoms are evaluated for clustering; empirical symptom cluster identification
studies that build upon that qualitative work; and studies identifying patient subgroups based on
empirically defined symptom clusters. This progression would enhance the validity and reproducibility of
symptom cluster research.
Scientists have explored demographic, personal, and clinical characteristics associated with
symptom clusters and cluster subgroups. There is also research evidence that symptom clusters influence
clinical outcomes including quality of life and survival. This information is important for the
identification of symptom cluster phenotypes—that is, subgroups with similar symptom patterns,
identifying characteristics, and probable outcomes. Continuing work is needed to identify high risk
groups (at risk for more severe symptoms and/or worse outcomes) that can be targeted for intervention
development and evaluation. Ultimately there is a need to demonstrate the value of symptom cluster
identification in guiding symptom assessment and management for cancer patients and survivors.
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Table 1. Identification of Symptom Clusters in Qualitative Research
Authors
Lopez, et al. 22

Sample
10 women in
U.K. with GYN
cancers

Design
Longitudinal:

Method
Content Analysis

Pre-treatment to
12 months posttreatment
39 interviews

Maguire, et al.
20

Molassiotis, et
al.21

10 individuals in
U.K. with
advanced lung
cancer reporting
3+ symptoms
17 individuals in
U.K. with
inoperable lung
cancer

Longitudinal:
2 interviews 3-5
weeks apart
Longitudinal:

Interpretative
Phenomenological
Analysis (IPA)

IPA

Symptom Clusters
1. Tiredness, sleeplessness, pain,
depression, weakness
2. Hair loss, ocular changes,
body image, identity
experience, anxiety
3. Nausea, appetite loss, taste
changes, bowel function,
weight changes, distress
4. Numbness-tingling in hands
and feet, restlessness,
sleeplessness, depression
1. Cough, pain, insomnia
2. Breathlessness, appetite loss,
weight loss
3. Fatigue, nocturia, disrupted
sleep
1. Cough, breathlessness, fatigue,
sleep disturbance, anxiety

Covariates/Outcomes
Physical symptoms interrelated with
depression, uncertainty, body image,
and identity as cancer patient.

Detrimental impact on physical
functioning





Beginning of
treatment, 3, 6, 12
months


Olver, et al.

35

42 cancer patients
in Australia with
chemotherapyinduced nausea

Cross-sectional

Thematic analysis

Cough associated with
sleeplessness;
Sleeplessness triggered fatigue;
Coughing worsened
breathlessness;
Breathlessness triggered anxiety

Separate concomitant symptoms
experienced with nausea:
vomiting, appetite changes, taste
changes, fatigue

15
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Table 2. A Priori Identification of Symptom Clusters in Quantitative Research
Authors
Cheng, et al.39

Ho, et al. 38

Hoffman, et
al.40

Jim, et al. 30

Sample
120 elderly
Chinese cancer
patients
undergoing
treatment

137 breast cancer
patients in U.S.
treated with
chemotherapy

80 newly
diagnosed lung
cancer patients in
U.S. undergoing
chemotherapy

78 U.S. women
with GYN
cancers being
treated with
chemotherapy

Design
Cross-sectional

Method
Multiple Regression

Symptom Distress
Scale (SDS); 4
symptoms
selected for
analysis

Independent
variables: symptoms

Longitudinal:

Symptom Clusters
Symptom cluster: pain, fatigue,
insomnia, mood disturbance




Dependent
variables: functional
status, quality of life
Path Analysis


Symptom cluster: Fatigue, sleep
disturbance, depression



Pre-, post, and 6-8
months



Validated
symptom scales



Cross-sectional

Multinomial loglinear modeling

Symptom cluster: pain, fatigue,
insomnia



Baseline
observation
Cancer Symptom
Experience
Inventory; 3
symptoms
selected for
analysis
Longitudinal:
Daily symptom
ratings for 7 days;
actigraph for 7
days



Latent Change
Scores

Symptom cluster: Fatigue, sleep
disturbance, depressed mood

Covariates/Patterns/Outcomes
20% of sample reported any 2
symptoms; 29%; reported any 3
symptoms; 33% reported all 4
symptoms
Low to moderate correlations
between symptom pairs
All 4 symptoms had independent
effects on quality of life
All symptoms were correlated at
each time point;
Prior symptom severity predicted
subsequent severity of same
symptom.
In pre-menopausal women,
baseline fatigue predicted posttreatment depression; and posttreatment fatigue predicted
depression at final follow-up.
3-way interaction among
symptoms
Covariates of age, comorbidities,
and stage of disease did not
improve the model

Symptoms occurred in cascade
pattern:
 Higher level of sleep disturbance
was associated with earlier peak
of fatigue
 Higher fatigue level was
associated with higher subsequent
16
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Lin, et al. 41

Oh, et al. 44

So, et al. 42

Stepanski, et
al.43

145 Chinese lung
cancer patients
post-surgery

110 South Korean
cancer patients
undergoing
treatment

Cross-sectional

Multiple regression

One week postsurgery

Independent
variables: symptoms

MD Anderson
Symptom
Inventory
(MDASI); 4
symptoms
selected based on
prevalence and
severity
Cross-sectional

Dependent variable:
quality of life

Validated
symptom scales

Symptom cluster
defined as two or
more symptoms
directly related to
each other and
indirectly related to
outcome

215 Chinese
women
undergoing
treatment for
breast cancer in
Hong Kong

Cross-sectional

11,445 U.S.
cancer patients
undergoing
treatment

Cross-sectional

During treatment

Path Analysis

Dependent variable:
functional
performance
Correlation;
Structural Equation
Modeling (SEM)

Symptom cluster: fatigue, pain,
sleep disturbance, distress



Symptom cluster: pain, insomnia,
depression, fatigue

During treatment
Patient Care





Symptom cluster:
Fatigue, pain, anxiety, depression

Validated
symptom scales
SEM: Test sample
and validation
sample



Symptom cluster:
Fatigue, trouble sleeping,
depressed mood, pain

depressed mood.
Presence of more symptoms
associated with poorer quality of
life
In hierarchical regression, fatigue,
sleep, and distress accounted for
72% of variance in quality of life

7 indirect paths between pain and
functional performance (paininsomnia, pain-depression, painfatigue, pain-depression-fatigue,
pain-insomnia-depressionfatigue)
3 indirect paths between insomnia
and functioning (insomniadepression, insomnia-fatigue,
insomnia-depression-fatigue)



Correlation among symptoms
supported existence of symptom
cluster
 More severe symptoms, treatment
with chemotherapy, and lower
social support was associated
with poorer quality of life
Direct effects:
 Fatigue, modeled as a latent
variable, was influenced by
depressed mood, trouble sleeping,
and pain.
17
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Monitor
 Validated
scale with 86
symptoms
 4 symptoms
included in
analysis

Indirect effects:
 effect of depressed mood on pain
mediated by trouble sleeping
 effect of trouble sleeping on
fatigue mediated by pain;
 effect of depressed mood on
fatigue mediated by trouble
sleeping and pain.
Cross-validation of model was
supported by validation sample

18
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Table 3. Empirical Identification of Symptom Clusters
Authors
Brown, et al. 45

Cheung, et al.46
Cheung, et al.47

Sample
196 U.S. women
6 months to 5
years postdiagnosis of Nonsmall cell lung
cancer

Design
Cross-sectional

1,366 Canadian
patients with
advanced cancer
attending
palliative care
clinics

Cross-sectional

Lung Cancer
Symptom Scale
(LCS)

Edmonton
Symptom
Assessment Scale
(ESAS)

Method
Novel strategy for
identification of
symptom clusters
using dummy codes

Principal
Components
Analysis (PCA)

Description of Clusters
1. 3-symptom cluster: no pattern
of symptoms across
participants
2. 4-symptom cluster: fatigue,
shortness of breath, cough,
anorexia
3. 5-symptom cluster: fatigue
shortness of breath, cough,
pain, anorexia (reported by
64% of sample)
4. 6-symptom cluster: 5symptom cluster plus
hemoptysis
1. Fatigue, drowsiness, nausea,
appetite, dyspnea
2. Anxiety, depression







Gleason, et al.
48

66 U.S. patients
newly diagnosed
with brain tumors
being treated with
radiotherapy

Longitudinal
Pre-treatment, end
of treatment
FACT-Brain
CESD-Depression

Exploratory Factor
Analysis (EFA)

1. Language: difficulty reading,
writing, finding works
2. Mood: sadness, anxiety,
depressed mood





Covariates/Patterns/Outcomes
Depressed mood, time since
diagnosis, number of
comorbidities, and current
treatment status were related to
overall symptom severity

Clusters 1 and 2 accounted for
45% and 10% of total variance,
respectively;
Clusters differed by primary
cancer site although cluster 2 was
consistent across sites
Clusters differed by age and and
gender: fatigue and drowsiness
were included in cluster 1 for
younger but not older patients; in
men, pain was part of cluster 2;
for women, physical and
psychological symptoms formed
separate clusters
A 3rd factor included only one
symptom, so it was dropped
Factor structure at end of
treatment was consistent with pretreatment
Multidimensional scaling and
cluster analysis supported 2factor structure
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Huang, et al. 49

111 Chinese
ovarian cancer
patients
undergoing
chemotherapy

Longitudinal

PCA

Pre-, during
chemotherapy
MSAS

Jimenez, et al.
16

Kenne
Sarenmalm, et
al.50

406 Spanish
patients with
advanced cancer
enrolled in a
palliative care
program

Cross-sectional

206 Swedish
breast cancer
patients
undergoing
treatment

Longitudinal

PCA

ESAS; 13 single
symptoms

PCA

Diagnosis, weeks
1 and 3, 6 months
MSAS

Kim, et al. 51

160 U.S. breast or
prostate cancer
patients being

Longitudinal
Pre-treatment,

EFA

Pre-treatment
1. Pain-related: Pain, bloating,
dizziness
2. Psychological: Nervous, sad,
anxious
3. Menopausal: Lack of energy,
dry mouth, difficulty sleeping,
sweats, lack of appetite,
irritation
Cycle 1
4. Gastro-intestinal: Nausea,
vomiting, weight loss
5. Body image: Hair loss,
constipation
Cycle 3
6. Neurological: Numbnesstingling, dizziness
1. Confusion cluster: agitation,
confusion, urinary
incontinence
2. Neuropsychological cluster:
Anxiety, depression, insomnia
3. Anorexia-cachexia cluster:
Anorexia, weight loss,
tiredness
4. GI cluster: Nausea, vomiting
1. Emotional: sad, nervous,
worry, difficulty sleeping,
quality of life
2. Unwell: drowsy, dry mouth,
appetite loss, irritability,
difficulty swallowing,
shortness of breath
3. GI: weight loss, taste change,
constipation, vomiting, hair
loss, nausea
Factor structure at middle of
radiotherapy:
1. Mood-cognitive:







Clusters 1, 2, and 3 were stable
across time points
The addition of new symptom
clusters may be attributed to
short- and long-term effects of
treatment.

Symptom clusters differed by
cancer site, gender, age, and
performance status
Survival was related to the
number of symptom clusters
present



PCA Clusters 1 and 3 were
consistent across all time points;
cluster 2 was less consistent



Symptom clusters identified at
end of treatment and one month
later were not identical to mid20
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treated with
radiotherapy

middle and end of
treatment, 1
month later
MSAS

Kim, et al. 52

282 U.S. breast
cancer patients
treated with
chemotherapy or
radiotherapy

Longitudinal

Common Factor
Analysis (CFA)

Pre-treatment,
during treatment,
end of treatment
20 symptoms
(some single
items, some
validated scales)

Kirkova, et al. 7
Walsh, et al. 53

922 U.S. patients
with advanced
cancer in
palliative care
program
Validation sample
of 181 patients

Cross-sectional
25 symptoms with
prevalence > 15%

Hierarchical Cluster
Analysis (HCA)

concentration, feeling nervous,
sadness, worry, itching,
irritability, skin changes
2. Sickness behavior: pain, lack
of energy, drowsiness, sleep
difficulty, sweating
3. Treatment-related: urinary
problems, diarrhea
Pre-treatment
1. Psycho-neurological:
Depressed mood, cognitive
disturbance, fatigue insomnia,
pain
First follow-up
1. Psycho-neurological (hot
flashes added)
2. Gastro-intestinal: nausea,
vomiting, low appetite
Second follow-up
1. Psycho-neurological
2. Gastro-intestinal
1. Fatigue-anorexia-cachexia
cluster: fatigue, lack of energy,
weakness, dry mouth,
anorexia, early satiety, taste
change, weight loss
2. Neuro-psychological cluster:
sleep problems, anxiety,
depression
3. Upper GI cluster: dizzy spells,
dyspepsia, belching, bloating
4. Nausea-vomiting cluster:
nausea, vomiting
5. Aero-digestive cluster:
dyspnea, cough, hoarseness,
dysphagia
6. Debility cluster: edema,
confusion
7. Pain cluster: pain, constipation

treatment clusters; however, the
mood-cognitive and sickness
behavior clusters were very
similar.






Clustering of symptoms was
consistent across treatment
trajectory
Demographic and clinical
variables did not influence
clustering

Kirkova: Validation study
clusters were similar but not
identical (8 clusters)
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Molassiotis, et
al.54

143 patients in U.
K. cancer centers

Longitudinal

PCA

Pre-treatment, 3,
6, 12 months later
MSAS

Olson, et al. 55

82 patients in
Canada receiving
palliative care

Longitudinal

SEM

1 month and 1
week before death

Exogenous
(background)
variables: pain,
anxiety, nausea,
shortness of breath,
drowsiness

ESAS

Pirri, et al. 56

Skerman, et
al.57

200 newly
diagnosed
Australian cancer
patients
undergoing
combined
modality
treatment
219 Australian
cancer patients

Longitudinal
Pre-, on-, posttreatment
EORTC QLQC30
Selby quality of
life scale
Longitudinal

Pre-treatment:
1. Nausea, vomiting, bloating
2. Numbness-tingling hands,
feet; swelling arms-legs
3. Hair loss; do not like self
4. Shortness of breath, cough
5. Difficulty swallowing, weight
loss, low appetite, vomiting,
pain
6. Feeling sad, worrying,
nervous, difficulty
concentrating, dizziness,
drowsiness, Irritability, lack of
energy
Stable effects across time periods:
 Drowsiness predicted appetite
 Drowsiness predicted tiredness
 Anxiety predicted depression

Endogenous
(dependent):
appetite, tiredness,
depression,
wellbeing
PCA used to identify 
any symptom cluster 
that included nausea
and vomiting

CFA

At subsequent time points, PCA used
again to determine core symptoms:
 At 3- and 6-month assessments,
core symptoms were maintained
but new symptoms entered some
clusters
 At 12 months, clusters decreased
in number of items
Overall, the six clusters remained
relatively consistent over time

Conclusion: There were different and
changing causal structures underlying
connections between symptoms

6-factor solution
Gastro-intestinal (GI) cluster
(nausea, vomiting, appetite
loss) at every time point



Over time, 5 consistent symptom
clusters were characterized:





Controlling for covariates, GI
cluster predicted overall quality
of life impairment at end of
treatment
The moderating effects of all 3
symptoms on quality of life was
stronger than any single symptom
or symptom pair
Several symptoms were
associated with different clusters
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being treated with
chemotherapy

Within 1 month of
initiating
chemotherapy, 6,
12 months later
Rotterdam
Symptom
Checklist—42
symptoms

Tsai, et al. 58

427 Taiwanese
patients with
advanced cancer
admitted to a
palliative care
unit

Cross-sectional
Upon admission
Face-valid
symptom
reporting scale—
15 items

PCA

1. Vasomotor: sweating, hot/cold
spells, night sweats
2. Oral discomforts: difficulty
swallowing, sore throat, sore
mouth, pain swallowing
3. Upper gastro-intestinal/aerodigestive discomforts:
indigestion, heartburn,
belching
4. Gastro-intestinal toxicities:
poor appetite, vomiting,
nausea, shivering, stomach
pain, trembling
5. Musculoskeletal discomforts,
lethargy: fatigue, sleepiness,
muscle soreness, weakness
1. Loss of energy: fatigue,
weakness
2. Poor intake: anorexia, taste
changes, dysphagia,
constipation, dry mouth
3. Autonomic dysfunction:
restlessness, heat, dizziness,
insomnia, night sweats
4. Aero-digestive impairment:
nausea, vomiting, abdominal
fullness, dyspnea
5. Pain



over time: poor appetite,
weakness, and fatigue
Vasomotor, oral, and
musculoskeletal clusters were
replicated over time, retaining
over 75% of the original
symptoms
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Table 4. Comparison of Methods for Identification of Symptom Clusters
Authors
Chen, E. 18
Fan, G. 19

Cheville, A.63,64

Henoch, I. 60

Sample
1296 Canadian
patients with
advanced cancer
referred to
outpatient
palliative care
service

2405 U.S. lung
cancer survivors
up to 5 years
post-diagnosis

400 Swedish
newly diagnosed
Swedish lung
cancer patients

Design
Longitudinal

Method
PCA, HCA, EFA

Baseline, 1-, 2-, 4, 8-, and 12-weeks

Clusters or Subgroups
Baseline:
PCA
1. Appetite, nausea, wellbeing, pain
2. Fatigue, drowsiness, dyspnea
3. Anxiety, depression



EFA:
1. Fatigue, drowsiness, dyspnea
wellbeing, appetite, pain, nausea,
2. Anxiety, depression





ESAS

Longitudinal:
1, 2, 3, 4, 5 years

HCA, EFA, Latent
Trait Analysis
(LTA)

LCS; single items:
sleep quality;
emotion, social,
cognitive
wellbeing

Cross-sectional
1 month postdiagnosis
SDS, EORTC
QLQ-C30
(the same 11
items from each

HCA re-dividing cluster 1:
1. Fatigue, drowsiness, dyspnea
2. Appetite, nausea, wellbeing, pain
3. Anxiety, depression
HCA: 1-5 years
1. Dyspnea, cough, fatigue
EFA
1. Dyspnea, cough, fatigue

Correlation, PCA,
HCA





LTA:
1. Fatigue, dyspnea, cough
2. Emotional wellbeing, sleep



Correlation: EORTC and SDS



1. Pain cluster: pain, bowel, nausea,
appetite, fatigue
2. Mood cluster: insomnia, mood,
concentration, outlook
3. Respiratory cluster (SDS only):
dyspnea, cough

Covariates/Outcomes
The number and composition
of symptom clusters varied
over time
Using the same analysis
method, clusters were
consistent over time
Symptom pairs (anxiety and
depression; fatigue and
drowsiness) were consistently
in the same cluster with
shifting of other symptoms
over time
Results for PCA and HCA
were more consistent across
methods than EFA
A single symptom cluster was
consistent across analytic
methods
Presence of the symptom
cluster, each component
symptom, and symptom pairs
were associated with
decreased survival
Differences were small
between the capacity of
symptom clusters, pairs or
individual symptoms to predict
survival
Clusters were judged to be
consistent across measures and
analytic methods
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scale)
PCA: EORTC and SDS
1. Pain cluster
2. Mood cluster
3. Respiratory cluster
HCA: EORTC and SDS
1. Mood cluster
2. Respiratory cluster
3. Pain cluster: pain, bowel, nausea
4. Appetite, fatigue: closely related
to each other and to pain cluster
Maliski, S. 65

402 U.S. men
with prostate
cancer
undergoing
treatment

Cross-sectional

FA, HCA

8-12 months posttreatment
PCI-SF: urinary,
sexual, bowel
dysfunction;
SF-36: fatigue,
pain, emotional
distress

Roiland, R. A.66 192 U.S. older
adult breast
cancer survivors

Cross-sectional
Baseline data
Symptom Bother
Scale (37 items)

EFA, CFA
SEM

FA:
1. Fatigue, emotional distress
2. Sexual and bowel dysfunction;
pain
[urinary dysfunction loaded equally
on both factors]
HCA: Subgroups
1. Most pain, some fatigue, some
sexual dysfunction (10%)
2. Most urinary and sexual
dysfunction (19%)
3. Most fatigue, most emotional
distress, some sexual dysfunction
(14%)
4. Most bowel dysfunction, some
sexual dysfunction (10%)
5. Minimal symptoms (48%)
1. Musculoskeletal: ache, stiffness,
pain, joint pain, weakness, fatigue
2. Neurocognitive: balance,
dizziness, memory problems,
concentration
3. Dryness: dry skin, itching, dry
mouth, thirst, shortness of breath



Composition of the clusters
was not consistent across
analytic methods



7-factor solution from EFA
had adequate fit in CFA
All 7 clusters were associated
with increased depression and
poorer quality of life
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Wikman, A. 67

402 Swedish
Cross-sectional
patients with
esophageal cancer EORTC QLQOES-18
completed 6
months after
surgery

PCA, HCA

4. Urinary: incontinence, increased
urination, decreased sex drive,
irritated eyes
5. Circulatory: hand-foot swelling,
taste or smell changes, hair
thinning or loss, constipation,
lymphedema, numbness
6. Sleep: frequent wakening, early
wakening, difficulty falling
asleep, vaginal discharge
7. Hormonal: mood swings,
depression, anxiety, nightmares,
hot flashes, headaches, vaginal
dryness
PCA and HCA solutions were
identical except diarrhea formed a
single symptom cluster using HCA;
PCA solution was accepted.
1. Fatigue/pain—fatigue, pain,
insomnia, dyspnea
2. Reflux/cough—dry mouth, taste
changes, cough, reflux
3. Eating difficulty—appetite loss,
dysphagia, eating difficulty,
nausea-vomiting

The reflux/cough and eating
difficulty symptom clusters were
associated with increased risk of
mortality
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Table 5. Empirical Identification of Symptom Cluster Subgroups
Authors
Dirksen, et al.
68

Sample
84 U.S. men with
prostate cancer
treated with
radiotherapy

Design
Longitudinal

Method
Latent Class
Analysis (LCA)

Pre-treatment,
post-treatment
Validated scales
Cluster: fatigue,
insomnia, pain,
depression,
anxiety,
treatment-related
(sexuality,
urinary, and
bowel symptoms)

Doong, et al. 69

398 U.S. women
with breast cancer
about to undergo
surgery

Cross-sectional

Latent Class Profile
Analysis (LCPA)

Pre-surgery

Subgroups
Pre-treatment groups:
1. Resilient (45%)—all low
symptoms
2. Adjusted (41%)—high
treatment-related symptoms;
low insomnia, depression,
anxiety
3. Distressed (4%)—All high
symptoms
4. Emerged (10%)—High fatigue,
depression, anxiety; low
treatment-related symptoms
Post-treatment groups:
 Groups 1-3 had similar results
 Group 4 changed to “Impacted”
(5%)—high pain, insomnia,
depression, urinary, bowel
symptoms
1. All low symptoms (61%)
2. All high symptoms (7%)
3. Low pain, high fatigue (32%)

Covariates/Patterns/Outcomes
All men in the emerging group
before treatment moved to
another group (66% moved to
Distress).
 Among those whose group
changed, there was a greater
probability of changing to a
group with higher symptom
levels.




Rare alleles of cytokine genes
(IL6 rs2069845, IL13
rs1295686, TNFα rs1800610)
had increased odds of being in
the all-high symptoms subgroup.



Subgroups with more severe
symptoms had poorer quality of
life

Validated Scales

Franceschini, et
al.70

140 Brazilian
Lung cancer
patients

Cluster: fatigue,
pain, sleep
disturbance,
depressive
symptoms
Cross-sectional
EORTC QLQC30; symptoms
selected for
anlaysis: fatigue,

HCA

1. Mild symptoms (60%)
2. Moderate symptoms (28%)
3. Severe symptoms (12%)
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Husain, et al. 71

221 U.S. patients
with advanced
cancer

pain, insomnia,
depression
Longitudinal

Cluster Analysis

Study entry,
weeks 2, 4, 8, 12
ESAS

Kim, et al. 72

282 U.S. breast
cancer patients
treated with
chemotherapy or
radiotherapy

Longitudinal
Pre-treatment,
during treatment,
end of treatment

HCA at each time
point
Logistic regression

Some validated
scales, some
single items

Kim, et al. 73

282 U.S. breast
cancer patients
treated with
chemotherapy or
radiotherapy

Cluster:
Depressed mood,
cognitive
disturbance,
fatigue, insomnia,
pain
Longitudinal
Pre-treatment,
during treatment,
end of treatment

HCA using
symptom severity
scores across three
time points
Logistic regression

Some validated
scales, some
single items

High-- tired; Moderate-drowsy, appetite, wellbeing,
pain, depression, anxiety (25%)
2. High-- tired; Moderate—
drowsy appetite, wellbeing;
Low—pain, depression, anxiety
(31%)
3. Low—tired, drowsy, appetite,
wellbeing, pain, depression,
anxiety (44%)
Pre-treatment
1. All low symptoms
2. High fatigue, low pain
3. High pain
4. All high symptoms
During-end of treatment
5. High depressed mood,
cognitive disturbance
6. High fatigue, insomnia



1. Gradually increasing symptoms
(26%)
2. Constantly low symptoms
(37%)
3. Dramatic increase and decrease
of symptoms (14%)
4. Constantly high symptoms
(13%)
5. Initially high symptoms with
dramatic decrease (10%)



1.








Subgroup membership predicted
quality of life over time
Grouping by symptom cluster
profiles did not add predictive
value to a widely used measure
of performance status in
palliative care

Subgroup membership changed
substantially across time except
for group 1.
Subgroup 4 (reference group)
differed from the other groups
on baseline performance status,
symptom burden, and treatment
modality; this pattern was
consistent across time.

Antecedents that distinguished
group 4 (reference group) from
other groups: baseline
performance status, previous
treatment, and education
Subgroup 4 had worse functional
limitations than other groups

Cluster:
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Liu, et al. 74

Reyes-Gibby,
et al. 75

76 U.S. women
with breast cancer
being treated with
anthracyclinebased
chemotherapy

599 U.S. newly
diagnosed lung
cancer patients

Depressed mood,
cognitive
disturbance,
fatigue, insomnia,
pain
Longitudinal:
Pre-treatment,
during each
treatment cycle
for 4 cycles (7
time points)
Validated scales
Cluster: fatigue,
sleep disturbance,
depression
Cross-sectional

Symptom Cluster Index (SCI)
groups based on scale cut-offs:
 SCI0: no symptoms (20%)
 SCI1: 1symptom (28%)
 SCI2: 2 symptoms (56%)
 SCI3: 3 symptoms (24%).



HCA
Logistic regression

1. Severe symptoms (16%)
2. Low intensity symptoms (30%)
3. High pain; low depressed
mood, fatigue
4. High fatigue; low depressed
mood, pain
5. High fatigue depressed mood;
low pain

Correlation;
Mixed effect models

SCI groups based on scale cut-offs:
 SCI0 (22%)
 SCI1 (28%)
 SCI2 (26%)
 SCI3-5 (24%)

Comparison of subgroups 1 and 2:
Additive effect of 5 alleles predicted
membership in high symptom group
controlling for disease stage and sex:
 ENOS -1474 T/A
 IL1β T-31C
 TNRR2 Met196 Arg
 PTGS2 exon10+8731>C
 IL1Orβ Lys47 Glu
 Fatigue, depression, cognitive
impairment: For each symptom,
SCI groups had similar
trajectories with symptoms
worsening during treatment.
 Sleep: There was no change in
sleep within subjects or between
groups.
 Anxiety: SCI groups had similar
trajectories with anxiety
improving over time.
 Higher SCI scores predicted
poorer quality of life.

Mixed effects model
Independent
variables: SCI
Dependent
variables: individual
symptom scores

Prior to treatment
Single items:
Cluster: Pain,
depressed mood,
fatigue

Sanford, et al.76

80 U.S. women
with breast cancer
being treated with
chemotherapy

Longitudinal:
Pre-treatment,
cycle 4 day 1, 6
months later
Validated
symptom scales
Cluster: fatigue,
sleep, depression,
anxiety, cognitive
impairment



Subgroups with higher SCI prior
to treatment had worse
symptoms during treatment
compared with lower SCI groups
Subgroups did not differ by
demographic or clinical factors
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Starkweather,
et al.77

128 U.S. women
with breast cancer

Cross-sectional
4 weeks after
breast surgery
before
chemotherapy

Cut-off scores,
extreme discordant
subgroup analysis,
median spit

Composite score: comparison of
groups with scores in the top and
bottom 20% of the sample




Extreme discordant scores: all
symptoms above cut-off



Using composite scores, high
and low symptom groups
differed on IL6 and IL7
Using discordant scores, groups
differed on IL7
Using median split, groups
differed on IL4 and IL5.

Validated scales
Cluster: fatigue,
depression, pain
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